Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle; Michael Steurer; Thomas Melchardt; Lukas Weiss; Franz Josef Gassner; Nadja Zaborsky; Roland Geisberger; Kemal Catakovic; Tanja Hartmann; Lisa Pleyer; Daniela Voskova; Josef Thaler; Alois Lang; Michael Girschikofsky; Andreas Petzer; Richard Greil

doi:10.1007/s00277-018-3403-9

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle (First author), Michael Steurer, Thomas Melchardt (Co-author), Lukas Weiss (Co-author), Franz Josef Gassner (Co-author), Nadja Zaborsky (Co-author), Roland Geisberger (Co-author), Kemal Catakovic, Tanja Hartmann (Co-author), Lisa Pleyer (Co-author), Daniela Voskova, Josef Thaler, Alois Lang, Michael Girschikofsky, Andreas Petzer, Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Correction › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	1745
Journal	ANNALS OF HEMATOLOGY
Volume	97
Issue number	9
DOIs	https://doi.org/10.1007/s00277-018-3403-9
Publication status	Published - 2018

Access to Document

10.1007/s00277-018-3403-9

Cite this

Egle, A., Steurer, M., Melchardt, T., Weiss, L., Gassner, F. J., Zaborsky, N., Geisberger, R., Catakovic, K., Hartmann, T., Pleyer, L., Voskova, D., Thaler, J., Lang, A., Girschikofsky, M., Petzer, A., & Greil, R. (2018). Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY , 97(9), 1745. https://doi.org/10.1007/s00277-018-3403-9

Egle, Alexander ; Steurer, Michael ; Melchardt, Thomas et al. / Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. In: ANNALS OF HEMATOLOGY 2018 ; Vol. 97, No. 9. pp. 1745.

@article{05dac949b9864ad79079ca7b4a5dc386,

title = "Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.",

author = "Alexander Egle and Michael Steurer and Thomas Melchardt and Lukas Weiss and Gassner, {Franz Josef} and Nadja Zaborsky and Roland Geisberger and Kemal Catakovic and Tanja Hartmann and Lisa Pleyer and Daniela Voskova and Josef Thaler and Alois Lang and Michael Girschikofsky and Andreas Petzer and Richard Greil",

note = "Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Dept Internal Med Hematol & Med Oncol 3, Salzburg, Austria;",

year = "2018",

doi = "10.1007/s00277-018-3403-9",

language = "English",

volume = "97",

pages = "1745",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

number = "9",

}

Egle, A, Steurer, M, Melchardt, T , Weiss, L , Gassner, FJ , Zaborsky, N , Geisberger, R, Catakovic, K, Hartmann, T, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A & Greil, R 2018, 'Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.', ANNALS OF HEMATOLOGY , vol. 97, no. 9, pp. 1745. https://doi.org/10.1007/s00277-018-3403-9

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. / Egle, Alexander (First author); Steurer, Michael; Melchardt, Thomas (Co-author) et al.
In: ANNALS OF HEMATOLOGY , Vol. 97, No. 9, 2018, p. 1745.

Research output: Contribution to journal › Correction › peer-review

TY - JOUR

T1 - Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

AU - Egle, Alexander

AU - Steurer, Michael

AU - Melchardt, Thomas

AU - Weiss, Lukas

AU - Gassner, Franz Josef

AU - Zaborsky, Nadja

AU - Geisberger, Roland

AU - Catakovic, Kemal

AU - Hartmann, Tanja

AU - Pleyer, Lisa

AU - Voskova, Daniela

AU - Thaler, Josef

AU - Lang, Alois

AU - Girschikofsky, Michael

AU - Petzer, Andreas

AU - Greil, Richard

N1 - Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Dept Internal Med Hematol & Med Oncol 3, Salzburg, Austria;

PY - 2018

Y1 - 2018

U2 - 10.1007/s00277-018-3403-9

DO - 10.1007/s00277-018-3403-9

M3 - Correction

C2 - 29934835

SN - 0939-5555

VL - 97

SP - 1745

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 9

ER -

Egle A, Steurer M, Melchardt T , Weiss L , Gassner FJ , Zaborsky N et al. Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY . 2018;97(9):1745. doi: 10.1007/s00277-018-3403-9